It is an ideal requirement to develop a gene expression vector that can be automatically regulated by physiological endogenous factors and realize the specific treatment of gene therapy in human body. For example, cardiovascular hypoxia expression regulation, adrenocortical hormone regulation, thyroid hormone regulation and other expression vectors. This vector can be expressed in vivo under hypoxia, and can also be expressed when the adrenal cortex rises rapidly in disease state. With the support of the National Natural Science Foundation of China (No.:3047203 1), Professor Kan Quancheng took human immunodeficiency virus and hepatitis B virus as the research objects, aimed at the characteristics of persistent infection of human immunodeficiency virus and hepatitis B virus, and combined with the negative feedback regulation mechanism of hepatitis C virus genome replication, constructed a cell gene therapy vector for targeted elimination of antigens such as hepatitis B and human immunodeficiency virus. This paper was published in the World Journal of Gastroenterology and was also included by SCI and Pub-Medline. The project also won the first prize of scientific and technological progress of Henan Provincial Department of Education and the second prize of scientific and technological progress of Henan Province, which indicated that the targeted therapy carrier based on physiological regulation began to obtain phased research results and effectively promoted the formation of a new research direction of gene therapy drugs.

At present, he has undertaken 1 project of the National Natural Science Foundation, 2 projects of the Tenth Five-Year Plan and 4 provincial scientific research projects, published more than 30 national scientific research papers, including 3 excerpts from SCI and 3 monographs, and won the Henan Science and Technology Progress Award 1 project and 3 third prizes. More than 20 graduate students and 3 doctoral students have been trained, and hundreds of pharmacists at all levels have been trained.